HAIC + Tislelizumab +lenvatinib
2026-CONV3RSION-01
Phase 2 other active
Quick answer
HAIC + Tislelizumab +lenvatinib for Hepatocellular Carcinoma (HCC) is a Phase 2 program (other) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Hepatocellular Carcinoma (HCC)
- Phase
- Phase 2
- Modality
- other
- Status
- active